Swing,

You wrote,, "We should get a boost from top line data (if positive)." Occaissionaly I have seen similar wording in other posts. I was under the impression that the drug itself has already proven its' efficacy. And this go-around was basically brought about by usnig a different inhaler mid-stream thus requiring additional data. Am I missing something? Furthermore, it is afterall an inhaler. How much technology can be involved in an inhaler? Perhaps I am a simpleton?